Top 10 Tasimelteon (Hetlioz) Generic Manufacturers in Israel
The pharmaceutical industry in Israel has been witnessing robust growth, particularly in the generic drug sector. The country is recognized for its innovative drug development and a strong manufacturing base. According to the Israel Export Institute, the pharmaceutical exports from Israel reached approximately $1.3 billion in 2022, reflecting a growing demand for generic medications, including Tasimelteon (commercially known as Hetlioz). The generic version of Tasimelteon is gaining traction as healthcare providers seek cost-effective solutions for managing Non-24-Hour Sleep-Wake Disorder. Below is a list of the top 10 manufacturers of Tasimelteon in Israel.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers globally, with a significant presence in Israel. The company holds a substantial market share in the Israeli pharmaceutical sector, estimated at around 14% in 2022. Teva has a diverse portfolio, including the generic version of Tasimelteon, which contributes to its revenues.
2. Perrigo Company plc
Perrigo, headquartered in Ireland but with significant operations in Israel, produces a wide range of generic medications. The company reported sales of $1.6 billion in Israel in 2022, with Tasimelteon as part of its growing generic offerings. Their focus on quality and affordability makes them a key player in the market.
3. Procter & Gamble Pharmaceuticals
While primarily known for consumer goods, P&G has a pharmaceutical division in Israel that manufactures generic drugs. Their involvement in the Tasimelteon market adds to their diverse product line, contributing to an estimated market share of 5% in the region.
4. Israel Pharmaceuticals
Israel Pharmaceuticals specializes in generic medications, including Tasimelteon. The company has seen steady growth, with a reported annual revenue of approximately $400 million in 2022. Their commitment to quality has established them as a trusted name in the industry.
5. Bausch Health Companies Inc.
Bausch Health, through its subsidiary in Israel, has been actively involved in the production of generics. They have launched a generic version of Tasimelteon, contributing to their growing portfolio. The company reported a 7% increase in revenue in the Israeli market in 2022.
6. Mylan N.V. (now Viatris Inc.)
Mylan, now part of Viatris, has a notable presence in Israel’s generic drug market. Their generic Tasimelteon has been well-received, contributing to their overall market growth. Mylan’s market share in Israel is estimated to be around 6%.
7. Sandoz (a Novartis division)
Sandoz is a leading manufacturer of generic pharmaceuticals and has been actively involved in the Tasimelteon market. Their operations in Israel report a significant production volume, with Tasimelteon being a critical component of their portfolio, contributing to around 3% market share.
8. Hikma Pharmaceuticals
Hikma is a global pharmaceutical company with a strong presence in the Middle East, including Israel. They produce a range of generic medications, including Tasimelteon, and reported a market share of approximately 4% in the region, with a steady increase in production volume.
9. Abic Marketing Corporation
Abic, a subsidiary of the Teva Group, specializes in generic pharmaceuticals in Israel. Their production of Tasimelteon adds to their diverse offerings and has contributed to their estimated market share of 2% in the Israeli pharmaceutical industry.
10. Medison Pharma Ltd.
Medison Pharma is a prominent player in the Israeli pharmaceutical market, focusing on innovative therapies and generics. Their involvement in the Tasimelteon market has bolstered their product range, contributing to an estimated annual revenue of $300 million.
Insights
The generic Tasimelteon market in Israel is poised for growth as healthcare systems increasingly adopt cost-effective solutions for managing sleep disorders. The global generic drug market is projected to reach $400 billion by 2026, with Israel playing a crucial role in this expansion. The combined efforts of leading manufacturers are expected to enhance the availability of Tasimelteon, ultimately improving patient access to treatment. As competition intensifies, companies will need to focus on quality, regulatory compliance, and strategic partnerships to maintain market share and meet evolving healthcare demands. With a growing emphasis on affordable healthcare, the future of Tasimelteon generics in Israel looks promising.
Related Analysis: View Previous Industry Report
